A method for metabolically engineering Saccharomyces cerevisiae to synthesize δ-tocotrienol from scratch
By integrating the photosynthesis bioδ-tocotrienol synthesis pathway in Saccharomyces cerevisiae, strengthening the precursor pathway and constructing substrate transport channels, overexpressing the transporter PDR11, the problem of low biosynthesis efficiency of δ-tocotrienol is solved. The efficient synthesis of δ-tocotrienol in Saccharomyces cerevisiae was achieved, providing a basis for the de novo synthesis of natural vitamin E.
Patent Information
- Application Number
- CN202310158802.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-02-24
AI Technical Summary
In the prior art, the biosynthesis efficiency of δ-tocotrienol in Saccharomyces cerevisiae is low, mainly due to the functional limitations of exogenous genes in cell factories, resulting in low synthesis product efficiency.
By integrating the δ-tocotrienol synthesis pathway from photosynthesis organisms, strengthening the precursor pathway, mutating the key enzymes in the δ-tocotrienol synthesis module, and constructing a substrate transport channel, overexpressing the transporter PDR11, making wine brewing Yeast can efficiently secrete and produce delta-tocotrienol.
The efficient synthesis of δ-tocotrienol in Saccharomyces cerevisiae was achieved, solving the problem of low catalytic efficiency caused by improper assembly of exogenous enzymes, and laying the foundation for the de novo synthesis of natural vitamin E in a specific configuration.
Smart Images

Figure CN116411013B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for metabolically engineering brewer's yeast to synthesize delta-tocotrienol from scratch, belonging to the technical field of metabolic engineering. Background Art
[0002] δ-Tocotrienol, as an isomer of vitamin E, not only has antioxidant effects, but also has attracted attention for its richer biological activities for human health, especially anti-cancer activity. Vitamin E is the general term for tocopherols and tocotrienols, including 8 compounds: α, β, γ, δ-tocopherol and α, β, γ, δ-tocotrienol. As one of the most important antioxidants, it is an essential vitamin for maintaining the body's metabolism, with a wide range of functions and a growing market demand. Although the chemical synthesis of vitamin E has been achieved since 1938, it is mainly synthesized by the "one-step condensation method" using two intermediates: 2,3,5-trimethylhydroquinone (main ring) and isophytol (side chain). The current technology is relatively mature, but it is widely used as an animal feed additive because it cannot synthesize vitamin monomers with specific stereo configurations, thereby affecting the activity of vitamin E. In 2018, China realized the synthesis of vitamin E by combining biological and chemical methods, but only microbial fermentation can be used to synthesize isophytol (C 20 H 40 ) is a precursor substance of farnesene (C 15 H 24 ), the synthesis process is still relatively complicated and mainly relies on chemical synthesis. At present, in health care, medical treatment, beauty and other aspects, people tend to choose naturally synthesized vitamin E. Existing natural vitamin E still mainly relies on plant extraction, which is limited by the limited plant resources and high cost. Therefore, it is a more convenient and economical way to artificially construct the biosynthetic pathway of vitamin E in microorganisms to achieve the de novo synthesis of natural vitamin E with a specific configuration by genetic engineering.
[0003] As a GRAS (Generally Regard as Safe) strain, Saccharomyces cerevisiae has been widely used in the biosynthesis of natural products such as terpenes and aromatic compounds. Compared with Escherichia coli, Saccharomyces cerevisiae has the advantages of high safety, low pathogenicity, high stress resistance, and low probability of phage contamination. In addition, Saccharomyces cerevisiae has higher tolerance to several isoprenoid compounds, such as farnesyl diphosphate (FPP) and geranyl diphosphate (GGPP) than Escherichia coli, and is more suitable for chassis cells for high-level production of isoprenoid compounds. Since GGPP is one of the key precursors in the δ-tocotrienol biosynthesis pathway, Saccharomyces cerevisiae is a host strain that is more conducive to the production of δ-tocotrienol. Saccharomyces cerevisiae does not have a δ-tocotrienol synthesis pathway, so it is necessary to use metabolic engineering to introduce the δ-tocotrienol synthesis pathway into Saccharomyces cerevisiae to construct a δ-tocotrienol production engineering strain. In recent years, some scholars have introduced the δ-tocotrienol synthesis pathway of photosynthetic organisms into Saccharomyces cerevisiae, achieving the de novo synthesis of δ-tocotrienol in Saccharomyces cerevisiae.
[0004] At present, although the de novo synthesis of δ-tocotrienol in Saccharomyces cerevisiae has been achieved, there is uncertainty in the expression, localization and assembly pattern of genes from photosynthetic organisms after they are introduced into Saccharomyces cerevisiae, which in turn causes a series of problems: the incorrect localization of heterologous enzymes leads to the separation of enzymes and substrates, the precursors required for the synthesis of products are consumed by endogenous competitive pathways, the expression imbalance between upstream and downstream enzymes, and the improper assembly of multiple exogenous enzymes makes it difficult to achieve synergistic catalysis, etc. These problems greatly limit the functionality of exogenous genes in cell factories, resulting in low efficiency of δ-tocotrienol biosynthesis. Summary of the invention
[0005] In order to solve the problem of low efficiency of δ-tocotrienol biosynthesis at present, the present invention provides a saccharomyces cerevisiae that can efficiently synthesize δ-tocotrienol, by integrating the δ-tocotrienol synthesis pathway from photosynthetic biological sources, strengthening the precursor pathway, mutating the key enzymes in the δ-tocotrienol synthesis module, constructing a substrate transport channel to assemble the key enzymes in the δ-tocotrienol synthesis module, and overexpressing the transporter PDR11, so that the saccharomyces cerevisiae can efficiently secrete and produce δ-tocotrienol extracellularly.
[0006] The first object of the present invention is to provide a method for metabolically engineering Saccharomyces cerevisiae to synthesize δ-tocotrienol from scratch, wherein the method is to integrate p-hydroxyphenylpyruvate dioxygenase HPPD, homogentisate geranylgeranyltransferase HGGT and truncated tocopherol cyclase tTC into the genome of Saccharomyces cerevisiae, and overexpress GGPP synthase CrtE and FPP synthase mutant FPS F112A .
[0007] Furthermore, the NCBI number of the para-hydroxyphenylpyruvate dioxygenase HPPD is NP_172144.3; the NCBI number of the homogentisate geranylgeranyltransferase HGGT is BAA17774; the amino acid sequence of the truncated tocopherol cyclase tTC is shown in SEQ ID NO.1; the NCBI number of the GGPP synthase CrtE is AAS49033.1; the FPP synthase mutant FPS F112A The amino acid sequence is shown in SEQ ID NO.2.
[0008] Furthermore, the gene encoding the p-hydroxyphenylpyruvate dioxygenase HPPD was inserted into the HO site of the Saccharomyces cerevisiae genome; the genes encoding the homogentisate geranylgeranyltransferase HGGT and the truncated tocopherol cyclase tTC were inserted into the DPP1 site of the Saccharomyces cerevisiae genome; the GGPP synthase CrtE and the FPP synthase mutant FPS F112A The coding gene was inserted into the GAL1-7 loci of the Saccharomyces cerevisiae genome.
[0009] Furthermore, the method further comprises mutating the truncated tocopherol cyclase tTC, and mutating the asparagine (N) at position 331 of the parent sequence of the amino acid sequence as shown in SEQ ID NO.1 to proline (P).
[0010] Furthermore, the method also includes overexpressing HPPD and HGGT-tTC assembled using the protein scaffold SH3 N331P Complex.
[0011] Furthermore, the complex is inserted into the 416d site of the Saccharomyces cerevisiae genome.
[0012] Furthermore, HGGT and tTC N331P A short protein connector (GGGGS)3 was used for fusion expression.
[0013] Furthermore, the nucleotide sequence of the protein scaffold SH3 is shown in SEQ ID NO.4.
[0014] Furthermore, the method also includes overexpressing the endogenous transport protein PDR11 to obtain the cerevisiae yeast that secretes and produces delta-tocotrienol.
[0015] Furthermore, in the method, Saccharomyces cerevisiae CEN PK2-1C is used as a host.
[0016] The second object of the present invention is to provide a saccharomyces cerevisiae that synthesizes delta-tocotrienol from scratch, wherein the saccharomyces cerevisiae is an saccharomyces cerevisiae host that integrates and expresses p-hydroxyphenylpyruvate dioxygenase HPPD, homogentisate geranylgeranyltransferase HGGT and truncated tocopherol cyclase tTC, and overexpresses GGPP synthase CrtE and FPP synthase mutant FPS. F112A .
[0017] Furthermore, the NCBI number of the para-hydroxyphenylpyruvate dioxygenase HPPD is NP_172144.3; the NCBI number of the homogentisate geranylgeranyltransferase HGGT is BAA17774; the amino acid sequence of the truncated tocopherol cyclase tTC is shown in SEQ ID NO.1; the NCBI number of the GGPP synthase CrtE is AAS49033.1; the FPP synthase mutant FPS F112A The amino acid sequence is shown in SEQ ID NO.2.
[0018] Furthermore, with promoter P ADH1 and P PGK1 Controls gene expression in the delta-tocotrienol biosynthesis pathway, P ADH1 The nucleotide sequence of is shown in SEQ ID NO.5, P PGK1 The nucleotide sequence is shown in SEQ ID NO.6.
[0019] Furthermore, the gene encoding the p-hydroxyphenylpyruvate dioxygenase HPPD was inserted into the HO site of the Saccharomyces cerevisiae genome; the genes encoding the homogentisate geranylgeranyltransferase HGGT and the truncated tocopherol cyclase tTC were inserted into the DPP1 site of the Saccharomyces cerevisiae genome; the GGPP synthase CrtE and the FPP synthase mutant FPS F112A The coding gene was inserted into the GAL1-7 loci of the Saccharomyces cerevisiae genome.
[0020] Furthermore, in the Saccharomyces cerevisiae, the truncated tocopherol cyclase tTC is a truncated tocopherol cyclase tTC mutant in which the asparagine (N) at position 331 of the parent sequence of the amino acid sequence as shown in SEQ ID NO.1 is mutated to proline (P).
[0021] Furthermore, in the Saccharomyces cerevisiae, HPPD and HGGT-tTC assembled using the protein scaffold SH3 are overexpressed. N331P Complex.
[0022] Furthermore, HGGT and tTC N331P A short protein connector (GGGGS)3 was used for fusion expression.
[0023] Furthermore, the nucleotide sequence of the protein scaffold SH3 is shown in SEQ ID NO.4.
[0024] Furthermore, in the Saccharomyces cerevisiae, the endogenous transporter PDR11 is overexpressed.
[0025] Furthermore, the Saccharomyces cerevisiae host is Saccharomyces cerevisiae CEN PK2-1C.
[0026] The third object of the present invention is to provide the use of the cerevisiae yeast in the fermentation production of delta-tocotrienol.
[0027] The beneficial effects of the present invention are:
[0028] The present invention constructs and optimizes the δ-tocotrienol synthesis pathway in Saccharomyces cerevisiae, and then obtains a Saccharomyces cerevisiae strain that efficiently produces δ-tocotrienol through extracellular secretion by constructing a substrate transport channel and overexpressing the transporter PDR11, laying a foundation for metabolic engineering of Saccharomyces cerevisiae to synthesize natural vitamin E of a specific configuration from scratch. The method for constructing the substrate transport channel provided by the present invention is simple and effective, and can solve the problem of low catalytic efficiency caused by improper assembly of multiple exogenous enzymes. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 is the δ-tocotrienol production of strains VE-2 and VE-3;
[0030] Figure 2 is the δ-tocotrienol production of strains VE-3 and VE-4;
[0031] Figure 3 is the δ-tocotrienol production of strains VE-4 and VE-5;
[0032] Figure 4 is the delta-tocotrienol production of strains VE-5 and VE-6. DETAILED DESCRIPTION
[0033] The present invention is further described below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0034] Detection methods involved: triple quadrupole composite linear ion trap liquid spectrometer, QTRAP 5500, ChromCore C8 column, mobile phase A is water (containing 0.1% FA), mobile phase B is acetonitrile, column temperature is 50°C, injection volume is 2μL, flow rate is 0.35mL / min, gradient elution program is 80% mobile phase B (0-1min); 99% mobile phase B (1-8min); 80% mobile phase B (8-10.5min), positive ion mode, ion pairs are 137 / 397 and 177 / 397.
[0035] Example 1: Construction of a recombinant Saccharomyces cerevisiae strain for de novo synthesis of delta-tocotrienol
[0036] According to the hydroxyphenylpyruvate dioxygenase HPPD from Arabidopsis thaliana (NCBI ID: NP_172144.3), the homogentisate geranylgeranyltransferase HGGT from Synechocystis sp. (NCBI ID: BAA17774), the truncated tocopherol cyclase tTC from Arabidopsis thaliana (based on NCBI ID: NP_567906.1, truncated by 47 amino acids, the amino acid sequence is shown in SEQ ID NO.1), the GGPP synthase CrtE from Taxus chinensis (NCBI ID: AAS49033.1), and the FPP synthase mutant FPS from chicken F112A (NCBI ID of the unmutated FPP synthase: P08836.2, on this basis, the phenylalanine at position 112 was mutated to alanine, and the amino acid sequence after mutation is shown in SEQ ID NO.2), codon optimization was performed according to the codon preference of Saccharomyces cerevisiae and the whole gene was synthesized.
[0037] Since Saccharomyces cerevisiae has the ability of homologous recombination, primers were designed according to the 45-50bp overlap of each adjacent fragment of the gene integration frame. Primers for amplifying the upstream and downstream homologous arms of the gene integration frame were designed on both sides of the integration site sequences of HO, DPP1 and GAL1~7 in the Saccharomyces cerevisiae genome, and the upstream and downstream homologous arms were amplified by PCR using Saccharomyces cerevisiae genomic DNA as a template. Primers were designed using plasmids pML104-HIS and pML104-TRP as templates, and the corresponding amino acid screening tags were amplified. Combined with the overlapping extension PCR primer design method, primers were designed to amplify the above-mentioned δ-tocotrienol synthesis pathway enzymes, promoters and terminators. HPPD, HGGT, tTC, CrtE and FPS synthesized by the whole gene were used. F112A The corresponding gene fragment was amplified using the plasmid as a template. The promoter P ADH1 and P PGK1 , terminator T CYC1 and TADH1 The corresponding gene expression cassette was obtained by overlap extension PCR.
[0038] According to the Cre-loxp system, the amplified upstream and downstream homology arms, amino acid screening tags and gene integration frames were transformed into Saccharomyces cerevisiae competent cells, and the correct transformants by colony PCR were picked for sequencing verification to obtain the recombinant Saccharomyces cerevisiae strain VE-2 with a de novo synthesis pathway for δ-tocotrienol.
[0039] In order to enhance the supply of precursor GGPP, the VE-2 strain was overexpressed with the GGPP synthase CrtE from Taxus chinensis and the FPP synthase mutant FPS from chicken. F112A . The upstream and downstream homology arms of the gene integration frame were designed on both sides of the GAL1-7 integration site sequence of the Saccharomyces cerevisiae genome, and the upstream and downstream homology arms were amplified by PCR using the Saccharomyces cerevisiae genomic DNA as a template. Primers were designed using plasmid pML104-LEU as a template to amplify the leucine selection tag. The CrtE and FPS synthesized by the whole gene F112A The corresponding gene fragment was amplified using the plasmid as a template. The promoter P ADH1 and P PGK1 , terminator T CYC1 and T ADH1 The corresponding gene expression cassette was obtained by overlap extension PCR. According to the Cre-loxp system gene editing method, the genetically engineered strain VE-3 for synthesizing δ-tocotrienol after optimizing the precursor pathway was obtained.
[0040] Building tTC N331P The mutant plasmid was synthesized with the whole gene as the template, and circular PCR was performed with primers N331-F and N331-R. The tTC was obtained by sequencing. N331P Mutant plasmids.
[0041] According to the above gene integration method, VE-3 was used as the starting strain, and tTC was integrated and expressed in DPP1. N331P The mutant was used to replace the unmutated tTC, and finally the genetically engineered strain VE-4 that synthesized delta-tocotrienol de novo was obtained.
[0042] Primer sequences:
[0043] N331-F: CTGAAAACGAACCACATGTTGTTGAATTAGAAGCTAGAACCAAC
[0044] N331-R: TCAACAACATGTGGTTCGTTTTCAGCAGTGATGTACCA.
[0045] Example 2: Construction of substrate transport pathway in the synthesis pathway of δ-tocotrienol
[0046] Construction of HGGT and tTC N331P Fusion expression plasmid pY16-HGGT-(GGGGS)3-tTC N331P , respectively synthesizing HGGT plasmid with the whole gene and constructing tTC N331P The mutant plasmid was used as a template to amplify HGGT using primers HGGT-F and HGGT-R, and primer tTC N331P -F and primer tTC N331P -R amplification of tTC N331P , using pY16-URA plasmid as template, the vector framework was amplified by primers pY16-F1 and pY16-R1. The obtained DNA fragment was purified and inserted into the pY16-URA vector by Gibson assembly method, and the plasmid pY16-HGGT-(GGGGS)3-tTC was obtained by sequencing. N331P .
[0047] Construction of HPPD and HGGT-tTC N331P Complex assembly expression plasmid pY16-HPPD-HGGT-tTC N331P -SH3, using the whole gene synthesis HPPD plasmid as a template, HPPD was amplified by primers HPPD-F and HPPD-R, and the plasmid pY16-HGGT-(GGGGS)3-tTC N331P As a template, the primer HGGT-tTC containing the SH3-ligand sequence N331P -F and primer HGGT-tTC N331P -R amplification of HGGT-tTC N331P The nucleotide sequence of SH3-ligand is shown in SEQ ID NO.3. The SH3-domain is amplified by primers SH3-F and SH3-R using the synthetic sequence SH3-domain as a template (the nucleotide sequence of SH3-domain is shown in SEQ ID NO.4). The promoter P is amplified by primers PF and PR using the genomic DNA of Saccharomyces cerevisiae as a template. ADH1 and P PGK1 , using pY16-URA plasmid as template, the vector framework was amplified by primers pY16-F2 and pY16-R2. The obtained DNA fragment was purified and inserted into the pY16-URA vector by Gibson assembly method, and the plasmid pY16-HPPD-HGGT-tTC was obtained by sequencing. N331P -SH3.
[0048] According to the gene integration method described in Example 1, VE-4 was used as the starting strain, and HPPD and HGGT-tTC assembled by SH3 were integrated at the 416d site. N331P The complex was constructed to construct a substrate transport channel and obtain a genetically engineered strain VE-5 that efficiently synthesizes delta-tocotrienol.
[0049] Primer sequences:
[0050] HGGT-F:CAAATATAAAACAATGGCTACTATTCAAGCTTTTTGGAG
[0051] HGGT-R: GCCACCGCCGCTTCCACCGCCACCAAAAATAGTATTAGAAAAATTTGGC AACCACAAAG
[0052] T8h N331P -F: GCGGTGGAAGCGGCGGTGGCGGAAGCATGGCTTCTATTAGTACTCCAA ACTCTG
[0053] T8h N331P -R: CATAAGAAATTCGCTCATAATCCAGGTGGCTTGAAGAATG
[0054] pY16-F1:CTGGATTATGAGCGAATTTCTTATGATTTATGATTTTTATTATTAAATAAG
[0055] pY16-R1:TAGTAGCCATTGTTTTATATTTGTTGTAAAAAAGTAGATAATTACTTCCTTG A
[0056] HPPD-F: GTACGGTGGAGGAGGAAGCGGCGGTGGCGGATCCGGTCACCAAAATGC TGCCG
[0057] HPPD-R: TAAGAAATTCGCTTAACCGACCAATTGCTTGGC
[0058] HGGT-tTC N331P -F: GAGGTAAGGCTGGTGGGGGGCTTCCGCCACCGCCGCTTCCACCGCCACCTAATCCAGGTGGCTTGAAAGAATG
[0059] HGGT-tTC N331P-R: CATACAATCAACTATGGCTACTATTCAAGCTTTTTGGAG
[0060] SH3-F: ATATAAAACAATGGCAGAGTATGTGCGTGCT
[0061] SH3-R: ACCGGATCCGCCACCGCCGCTTCCTCCTCCACCGTACTTCTCCACATAAGG AACG
[0062] PF: GAATAGTAGCCATAGTTGATTGTATGCTTTGGTATAGCTTG
[0063] PR: TACTCTGCCATTGTTTTATATTTGTTGTAAAAAAGTAGATAATTACTTC
[0064] pY16-F2: TGGTCGGTTAAGCGAATTTCTTATGATTTATGATTTTTATTATTAAATAAG pY16-R2: AAGCCCCCCACCAGCCTTACCTCCTAAGCGTAGACGTTAATCATGTAATT AGTTATGTCACGCTTACATTC.
[0065] Example 3: Production of δ-tocotrienol by extracellular secretion
[0066] The pY16-PDR11 plasmid was constructed. PDR11 was amplified using the yeast genome as a template using primers PDR11-F and PDR11-R. The pY16-URA plasmid was used as a template and the vector framework was amplified using primers pY16-F3 and pY16-R3. The obtained DNA fragment was purified and inserted into the pY16-URA vector by the Gibson assembly method. The plasmid pY16-PDR11 was obtained by sequencing.
[0067] The plasmid pY16-PDR11 was transformed into the VE-5 strain to obtain the extracellular secretion-producing δ-tocotrienol strain VE-6.
[0068] Shake flask fermentation method:
[0069] (1) The recombinant strains VE-2, VE-3, VE-4, VE-5 and VE-6 were streaked onto YPD plates and cultured at 30°C until a large number of colonies grew.
[0070] (2) Inoculate a loopful of a single colony into the seed medium and culture at 30°C and 220 rpm for 20 h.
[0071] (3) Inoculate the seed culture solution into the fermentation medium at an initial inoculum of 2%, culture at 30°C, 220 rpm for 48 h, add 50% (v / v) dodecane, and continue to culture at 30°C, 220 rpm for 144 h. Measure OD 600 Afterwards, the bacterial solution was transferred to a 50 mL centrifuge tube and centrifuged at 6000 rpm for 10 min at room temperature. 1 mL of the organic phase was taken and evaporated in a vacuum rotary evaporator, then re-dissolved in 1 mL of acetonitrile and filtered through a 0.22 μm organic filter membrane, and then quantitatively analyzed using a triple quadrupole composite linear ion trap liquid chromatography-mass spectrometer.
[0072] Primer sequences:
[0073] PDR11-F: TAGAACTAGTGGATCCCCCGGCGGATGTCTCTTTCCAAATAT
[0074] PDR11-R: GACGGTATCGATAAGCTTGATTATACGCTTTGTTCGTTTGGAT
[0075] pY16-F3:CGGGGGATCCACTAGTTCTA
[0076] pY16-R3: TCAAGCTTATCGATACCGTCG.
[0077] Comparison of shake flask fermentation results of strains VE-2 and VE-3 Figure 1 As shown, the δ-tocotrienol production of strains VE-2 and VE-3 was 59.2 μg / L and 384.5 μg / L, respectively. Compared with strain VE-2, the δ-tocotrienol production of strain VE-3 was increased by 5.5 times to verify the overexpression of GGPP synthase CrtE from Taxus chinensis and FPP synthase mutant FPS from chicken F112A , the effect of enhancing the GGPP supply on improving the synthesis of δ-tocotrienol.
[0078] Comparison of shake flask fermentation results of strains VE-3 and VE-4 Figure 2 As shown, the δ-tocotrienol production of strain VE-4 was 1.8 times that of strain VE-3, reaching 703.7 μg / L, in order to verify the effect of site-directed mutation of tocopherol cyclase tTC on increasing the δ-tocotrienol production.
[0079] Comparison of shake flask fermentation results of strains VE-4 and VE-5 Figure 3As shown, the δ-tocotrienol production of strain VE-5 was 1801.5 μg / L. Compared with strain VE-4, the δ-tocotrienol production of strain VE-5 was increased by 1.6 times, verifying the effect of constructing a substrate transport channel on increasing the δ-tocotrienol production.
[0080] Comparison of shake flask fermentation results of strains VE-5 and VE-6 Figure 4 As shown, the δ-tocotrienol production of strain VE-6 was 1.7 times that of strain VE-5, reaching 3062.6 μg / L, which verified the effect of extracellular secretion in the efficient production of δ-tocotrienol.
[0081] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A method for metabolically engineering Saccharomyces cerevisiae to synthesize δ-tocotrienol from scratch, characterized in that: The method is to integrate p-hydroxyphenylpyruvate dioxygenase HPPD, homogentisate geranylgeranyltransferase HGGT and truncated tocopherol cyclase tTC into the genome of Saccharomyces cerevisiae, and overexpress GGPP synthase CrtE and FPP synthase mutant FPS F112A ; The NCBI number of the para-hydroxyphenylpyruvate dioxygenase HPPD is NP_172144.3; the NCBI number of the homogentisate geranylgeranyltransferase HGGT is BAA17774; the amino acid sequence of the truncated tocopherol cyclase tTC is shown in SEQ ID NO.1; the NCBI number of the GGPP synthase CrtE is AAS49033.1; the FPP synthase mutant FPS F112A The amino acid sequence is shown in SEQ ID NO.
2.
2. The method according to claim 1, characterized in that: The method further comprises mutating the truncated tocopherol cyclase tTC, and mutating the asparagine at position 331 of the parent sequence of the amino acid sequence as shown in SEQ ID NO.1 to proline.
3. The method according to claim 1 or 2, characterized in that: The method also includes overexpressing HPPD and HGGT-tTC assembled using protein scaffold SH3 N331P Complex, wherein the nucleotide sequence of the protein scaffold SH3 is as shown in SEQ ID NO.
4.
4. The method according to claim 3, characterized in that HGGT and tTC N331P A short protein linker (GGGGS) 3 was used for fusion expression.
5. The method according to claim 1, characterized in that The method further comprises overexpressing the endogenous transporter PDR11 to obtain the cerevisiae yeast that secretes and produces delta-tocotrienol.
6. A cerevisiae yeast for synthesizing delta-tocotrienol from scratch, characterized in that: The brewer's yeast is a yeast host that integrates and expresses p-hydroxyphenylpyruvate dioxygenase HPPD, homogentisate geranylgeranyltransferase HGGT and truncated tocopherol cyclase tTC on its genome, and overexpresses GGPP synthase CrtE and FPP synthase mutant FPS. F112A ; The NCBI number of the para-hydroxyphenylpyruvate dioxygenase HPPD is NP_172144.3; the NCBI number of the homogentisate geranylgeranyltransferase HGGT is BAA17774; the amino acid sequence of the truncated tocopherol cyclase tTC is as shown in SEQ ID NO.1, or the asparagine at position 331 of the parent sequence of the amino acid sequence as shown in SEQ ID NO.1 is mutated to proline; the NCBI number of the GGPP synthase CrtE is AAS49033.1; the FPP synthase mutant FPS F112A The amino acid sequence is shown in SEQ ID NO.
2.
7. The brewer's yeast according to claim 6, characterized in that In the Saccharomyces cerevisiae, HPPD and HGGT-tTC assembled using the protein scaffold SH3 were overexpressed. N331P complex; wherein the nucleotide sequence of the protein scaffold SH3 is as shown in SEQ ID NO.4, HGGT and tTC N331P A short protein linker (GGGGS) 3 was used for fusion expression.
8. The brewer's yeast according to claim 6, characterized in that In the Saccharomyces cerevisiae, the endogenous transporter PDR11 was overexpressed.
9. Use of the cerevisiae yeast according to any one of claims 6 to 8 in the fermentation production of delta-tocotrienol.
Citation Information
Patent Citations
Enzymes expressed in saccharomyces cerevisiae, genetically engineered bacterium highly producing alpha- and gamma-tocotrienols as well as construction method of genetically engineered bacterium
CN110423732A
Recombinant saccharomyces cerevisiae strain for synthesizing delta-tocotrienols and construction method and use
CN111235044A
Recombinant yarrowia lipolytica for high-yield production of tocotrienols, and construction method and application thereof
CN113736677A
Recombinant engineering strain with high yield of tocotrienols as well as construction method and application thereof
CN113930350A
